In this study, previously untreated patients with advanced NSCLC harboring no EGFR mutation or ALK rearrangement were stratified at randomization based on region of enrollment, performance status, histology, and PD-L1 expression (34). This evidence concerns the gene CD274 and non-small cell lung carcinoma.